Other (Bladder Cancer, Sexual Dysfunction)

  • Jacques Corcos
  • Mikolaj Przydacz


  • Bladder cancer is a significant oncologic complication in patients suffering from neurogenic lower urinary tract dysfunction. Available data suggest that bladder cancer occurs more often in neurogenic individuals than in the general population. It is also associated with significant mortality. Several risk factors have been identified, but the proposed screening strategies still remain a matter of dispute because available screening tests do not fulfill multiple criteria of a proper screening test. The potential morbidity, financial burden, and lack of proven benefit discourage currently available screening strategies in this specific population.

  • Neurogenic individuals continue to have active sexual lives and to consider sexuality as one of their priorities. Sexual dysfunction is highly prevalent and adversely affects the quality of life of neurogenic patients. Neurogenic sexual dysfunction remains difficult to diagnose and treat effectively. Neurogenic patients, regardless of sex, should be specifically queried about sexual function. In males, treatment includes oral and local pharmacotherapy, mechanical (vacuum constriction) devices, and prosthetics. Treatment of sexual dysfunction in neurologically impaired women is rather limited and poorly studied.


Bladder cancer Cystoscopy Cytology Screening Erectile dysfunction Phosphodiesterase type 5 inhibitors Vacuum constriction devices Intracavernosal injection Penile prosthesis 


  1. 1.
    Gui-Zhong L, Li-Bo M. Bladder cancer in individuals with spinal cord injuries: a meta-analysis. Spinal Cord. 2017;55(4):341–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Hess MJ, Zhan EH, Foo DK, Yalla SV. Bladder cancer in patients with spinal cord injury. J Spinal Cord Med. 2003;26(4):335–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Groah SL, Weitzenkamp DA, Lammertse DP, Whiteneck GG, Lezotte DC, Hamman RF. Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil. 2002;83(3):346–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Pannek J. Transitional cell carcinoma in patients with spinal cord injury: a high risk malignancy? Urology. 2002;59(2):240–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Subramonian K, Cartwright RA, Harnden P, Harrison SC. Bladder cancer in patients with spinal cord injuries. BJU Int. 2004;93(6):739–43.PubMedCrossRefGoogle Scholar
  6. 6.
    Kalisvaart JF, Katsumi HK, Ronningen LD, Hovey RM. Bladder cancer in spinal cord injury patients. Spinal Cord. 2010;48(3):257–61.PubMedCrossRefGoogle Scholar
  7. 7.
    Welk B, McIntyre A, Teasell R, Potter P, Loh E. Bladder cancer in individuals with spinal cord injuries. Spinal Cord. 2013;51(7):516–21.PubMedCrossRefGoogle Scholar
  8. 8.
    Austin JC, Elliott S, Cooper CS. Patients with spina bifida and bladder cancer: atypical presentation, advanced stage and poor survival. J Urol. 2007;178(3 Pt 1):798–801.PubMedCrossRefGoogle Scholar
  9. 9.
    Kyritsis AP, Boussios S, Pavlidis N. Cancer specific risk in multiple sclerosis patients. Crit Rev Oncol Hematol. 2016;98:29–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Ajdacic-Gross V, Rodgers S, Aleksandrowicz A, Mutsch M, Steinemann N, von Wyl V, et al. Cancer co-occurrence patterns in Parkinson’s disease and multiple sclerosis-do they mirror immune system imbalances? Cancer Epidemiol. 2016;44:167–73.PubMedCrossRefGoogle Scholar
  11. 11.
    Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 1992;6(1):1–30.PubMedGoogle Scholar
  12. 12.
    Nahm LS, Chen Y, DeVivo MJ, Lloyd LK. Bladder cancer mortality after spinal cord injury over 4 decades. J Urol. 2015;193(6):1923–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Stonehill WH, Dmochowski RR, Patterson AL, Cox CE. Risk factors for bladder tumors in spinal cord injury patients. J Urol. 1996;155(4):1248–50.PubMedCrossRefGoogle Scholar
  14. 14.
    West DA, Cummings JM, Longo WE, Virgo KS, Johnson FE, Parra RO. Role of chronic catheterization in the development of bladder cancer in patients with spinal cord injury. Urology. 1999;53(2):292–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Hollingsworth JM, Rogers MA, Krein SL, Hickner A, Kuhn L, Cheng A, et al. Determining the noninfectious complications of indwelling urethral catheters: a systematic review and meta-analysis. Ann Intern Med. 2013;159(6):401–10.PubMedCrossRefGoogle Scholar
  16. 16.
    Ghoniem G. Complications related to neurogenic bladder dysfunction I: infection, lithiasis, and neoplasia. In: Corcos J, Ginsberg D, Karsenty G, editors. Textbook of the neurogenic bladder. 3rd ed. Boca Raton: CRC Press/Taylor & Francis; 2016. p. 699–708.Google Scholar
  17. 17.
    Vaidyanathan S, Mansour P, Soni BM, Singh G, Sett P. The method of bladder drainage in spinal cord injury patients may influence the histological changes in the mucosa of neuropathic bladder—a hypothesis. BMC Urol. 2002;2:5.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Feifer A, Corcos J. Contemporary role of suprapubic cystostomy in treatment of neuropathic bladder dysfunction in spinal cord injured patients. Neurourol Urodyn. 2008;27(6):475–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Hoen L, Ecclestone H, Blok BF, Karsenty G, Phe V, Bossier R, et al. Long-term effectiveness and complication rates of bladder augmentation in patients with neurogenic bladder dysfunction: a systematic review. Neurourol Urodyn. 2017. (Epub ahead of print); doi: 10.1002/nau.23205.
  20. 20.
    Higuchi TT, Granberg CF, Fox JA, Husmann DA. Augmentation cystoplasty and risk of neoplasia: fact, fiction and controversy. J Urol. 2010;184(6):2492–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Biardeau X, Chartier-Kastler E, Roupret M, Phe V. Risk of malignancy after augmentation cystoplasty: a systematic review. Neurourol Urodyn. 2016;35(6):675–82.PubMedCrossRefGoogle Scholar
  22. 22.
    Bothig R, Kurze I, Fiebag K, Kaufmann A, Schops W, Kadhum T, et al. Clinical characteristics of bladder cancer in patients with spinal cord injury: the experience from a single centre. Int Urol Nephrol. 2017;49(6):983–94.PubMedCrossRefGoogle Scholar
  23. 23.
    Navon JD, Soliman H, Khonsari F, Ahlering T. Screening cystoscopy and survival of spinal cord injured patients with squamous cell cancer of the bladder. J Urol. 1997;157(6):2109–11.PubMedCrossRefGoogle Scholar
  24. 24.
    El Masri WS, Patil S, Prasanna KV, Chowdhury JR. To cystoscope or not to cystoscope patients with traumatic spinal cord injuries managed with indwelling urethral or suprapubic catheters? That is the question! Spinal Cord. 2014;52(1):49–53.CrossRefGoogle Scholar
  25. 25.
    Yang CC, Clowers DE. Screening cystoscopy in chronically catheterized spinal cord injury patients. Spinal Cord. 1999;37(3):204–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Hamid R, Bycroft J, Arya M, Shah PJ. Screening cystoscopy and biopsy in patients with neuropathic bladder and chronic suprapubic indwelling catheters: is it valid? J Urol. 2003;170(2 Pt 1):425–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Cameron AP, Rodriguez GM, Schomer KG. Systematic review of urological followup after spinal cord injury. J Urol. 2012;187(2):391–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Fort ML, Perrouin-Verbe MA, Labat JJ. Evolution and follow-up of lower urinary tract dysfunction in spinal cord–injured patients. In: Corcos J, Ginsberg D, Karsenty G, editors. Textbook of the neurogenic bladder. 3rd ed. Boca Raton: CRC Press/Taylor & Francis; 2016. p. 773–80.Google Scholar
  29. 29.
    MacLennan GT, Larchian WA, Cheng L, Bodner DR, Hardin BM, Goldman HB, et al. Pathology–endoscopy correlations of bladder, urachal, and urethral lesions. In: Hansel DE, McKenney JK, Stephenson AJ, Chang SS, editors. The urinary tract: a comprehensive guide to patient diagnosis and management. New York: Springer Science+Business Media; 2012. p. 311–22.CrossRefGoogle Scholar
  30. 30.
    Sammer U, Walter M, Knupfer SC, Mehnert U, Bode-Lesniewska B, Kessler TM. Do we need surveillance urethro-cystoscopy in patients with neurogenic lower urinary tract dysfunction? PLoS One. 2015;10(10):e0140970.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Stonehill WH, Goldman HB, Dmochowski RR. The use of urine cytology for diagnosing bladder cancer in spinal cord injured patients. J Urol. 1997;157(6):2112–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Gormley EA. Urologic complications of the neurogenic bladder. Urol Clin North Am. 2010;37(4):601–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Kaufman JM, Fam B, Jacobs SC, Gabilondo F, Yalla S, Kane JP, et al. Bladder cancer and squamous metaplasia in spinal cord injury patients. J Urol. 1977;118(6):967–71.PubMedCrossRefGoogle Scholar
  34. 34.
    Broecker BH, Klein FA, Hackler RH. Cancer of the bladder in spinal cord injury patients. J Urol. 1981;125(2):196–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Bejany DE, Lockhart JL, Rhamy RK. Malignant vesical tumors following spinal cord injury. J Urol. 1987;138(6):1390–2.PubMedCrossRefGoogle Scholar
  36. 36.
    Bickel A, Culkin DJ, Wheeler JS Jr. Bladder cancer in spinal cord injury patients. J Urol. 1991;146(5):1240–2.PubMedCrossRefGoogle Scholar
  37. 37.
    Stamatiou K, Papadoliopoulos I, Dahanis S, Zafiropoulos G, Polizois K. The accuracy of ultrasonography in the diagnosis of superficial bladder tumors in patients presenting with hematuria. Ann Saudi Med. 2009;29(2):134–7.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Mirkin K, Casey JT, Mukherjee S, Kielb SJ. Risk of bladder cancer in patients with spina bifida: case reports and review of the literature. J Pediatr Rehabil Med. 2013;6(3):155–62.PubMedGoogle Scholar
  39. 39.
    Power NE, Izawa J. Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer. 2016;2(1):27–36.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    European Association of Urology (EAU). Oncology guidelines [internet]. Muscle-invasive and metastatic bladder cancer, 2017. Accessed 29 May 2017.
  41. 41.
    European Association of Urology (EAU). Oncology guidelines [internet]. Non-muscle-invasive bladder cancer, 2017. Accessed 29 May 2017.
  42. 42.
    Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol 2017 (in press). doi: 10.1016/j.juro.2017.04.086.
  43. 43.
    Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Kassouf W, Traboulsi SL, Kulkarni GS, Breau RH, Zlotta A, Fairey A, et al. CUA guidelines on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2015;9(9-10):E690–704.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Albersen M, De Ridder D. Sexual consequences of multiple sclerosis and other central nervous system disorders. In: Corcos J, Ginsberg D, Karsenty G, editors. Textbook of the neurogenic bladder. 3rd ed. Boca Raton: CRC Press/Taylor & Francis; 2016. p. 741–53.Google Scholar
  46. 46.
    Alexander CJ, Sipski ML, Findley TW. Sexual activities, desire, and satisfaction in males pre- and post-spinal cord injury. Arch Sex Behav. 1993;22(3):217–28.PubMedCrossRefGoogle Scholar
  47. 47.
    Reitz A, Tobe V, Knapp PA, Schurch B. Impact of spinal cord injury on sexual health and quality of life. Int J Impot Res. 2004;16(2):167–74.PubMedCrossRefGoogle Scholar
  48. 48.
    Ferreiro-Velasco ME, Barca-Buyo A, de la Barrera SS, Montoto-Marques A, Vazquez XM, Rodriguez-Sotillo A. Sexual issues in a sample of women with spinal cord injury. Spinal Cord. 2005;43(1):51–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Kreuter M, Siosteen A, Biering-Sorensen F. Sexuality and sexual life in women with spinal cord injury: a controlled study. J Rehabil Med. 2008;40(1):61–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Kreuter M, Sullivan M, Siosteen A. Sexual adjustment and quality of relationship in spinal paraplegia: a controlled study. Arch Phys Med Rehabil. 1996;77(6):541–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Biering-Sorensen F, Sonksen J. Penile erection in men with spinal cord or cauda equina lesions. Semin Neurol. 1992;12(2):98–105.PubMedCrossRefGoogle Scholar
  52. 52.
    Chehensse C, Bahrami S, Denys P, Clement P, Bernabe J, Giuliano F. The spinal control of ejaculation revisited: a systematic review and meta-analysis of anejaculation in spinal cord injured patients. Hum Reprod Update. 2013;19(5):507–26.PubMedCrossRefGoogle Scholar
  53. 53.
    Courtois F, Charvier K. Sexual dysfunction in patients with spinal cord lesions. Handb Clin Neurol. 2015;130:225–45.PubMedCrossRefGoogle Scholar
  54. 54.
    Lew-Starowicz M, Rola R. Prevalence of sexual dysfunctions among women with multiple sclerosis. Sex Disabil. 2013;31(2):141–53.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Zorzon M, Zivadinov R, Bosco A, Bragadin LM, Moretti R, Bonfigli L, et al. Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Mult Scler. 1999;5(6):418–27.PubMedGoogle Scholar
  56. 56.
    Boller F, Agrawal K, Romano A. Sexual function after strokes. Handb Clin Neurol. 2015;130:289–95.PubMedCrossRefGoogle Scholar
  57. 57.
    Roumiguie M, Guillotreau J, Castel-Lacanal E, Malavaud B, De Boissezon X, Marque P, et al. Assessment of sexual function in men with idiopathic Parkinson’s disease using the international index of erectile dysfunction (IIEF-15). Prog Urol. 2011;21(1):67–71.PubMedCrossRefGoogle Scholar
  58. 58.
    Bronner G, Royter V, Korczyn AD, Giladi N. Sexual dysfunction in Parkinson’s disease. J Sex Marital Ther. 2004;30(2):95–105.PubMedCrossRefGoogle Scholar
  59. 59.
    Wermuth L, Stenager E. Sexual problems in young patients with Parkinson’s disease. Acta Neurol Scand. 1995;91(6):453–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Meco G, Rubino A, Caravona N, Valente M. Sexual dysfunction in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14(6):451–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Koller WC, Vetere-Overfield B, Williamson A, Busenbark K, Nash J, Parrish D. Sexual dysfunction in Parkinson’s disease. Clin Neuropharmacol. 1990;13(5):461–3.PubMedCrossRefGoogle Scholar
  62. 62.
    Kirchhof K, Apostolidis AN, Mathias CJ, Fowler CJ. Erectile and urinary dysfunction may be the presenting features in patients with multiple system atrophy: a retrospective study. Int J Impot Res. 2003;15(4):293–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol. 1994;151(5):1336–41.PubMedCrossRefGoogle Scholar
  64. 64.
    Decter RM, Furness PD 3rd, Nguyen TA, McGowan M, Laudermilch C, Telenko A. Reproductive understanding, sexual functioning and testosterone levels in men with spina bifida. J Urol. 1997;157(4):1466–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Game X, Moscovici J, Game L, Sarramon JP, Rischmann P, Malavaud B. Evaluation of sexual function in young men with spina bifida and myelomeningocele using the international index of erectile function. Urology. 2006;67(3):566–70.PubMedCrossRefGoogle Scholar
  66. 66.
    Cass AS, Bloom BA, Luxenberg M. Sexual function in adults with myelomeningocele. J Urol. 1986;136(2):425–6.PubMedCrossRefGoogle Scholar
  67. 67.
    Sawyer SM, Roberts KV. Sexual and reproductive health in young people with spina bifida. Dev Med Child Neurol. 1999;41(10):671–5.PubMedCrossRefGoogle Scholar
  68. 68.
    Kessler TM, Fowler CJ, Panicker JN. Sexual dysfunction in multiple sclerosis. Expert Rev Neurother. 2009;9(3):341–50.PubMedCrossRefGoogle Scholar
  69. 69.
    Fletcher SG, Castro-Borrero W, Remington G, Treadaway K, Lemack GE, Frohman EM. Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol. 2009;6(2):96–107.PubMedCrossRefGoogle Scholar
  70. 70.
    Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res. 2000;12(6):305–11.PubMedCrossRefGoogle Scholar
  71. 71.
    Condra M, Morales A, Owen JA, Surridge DH, Fenemore J. Prevalence and significance of tobacco smoking in impotence. Urology. 1986;27(6):495–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Horowitz JD, Goble AJ. Drugs and impaired male sexual function. Drugs. 1979;18(3):206–17.PubMedCrossRefGoogle Scholar
  73. 73.
    Basson R, Wierman ME, van Lankveld J, Brotto L. Summary of the recommendations on sexual dysfunctions in women. J Sex Med. 2010;7(1 Pt 2):314–26.PubMedCrossRefGoogle Scholar
  74. 74.
    Laan E, Both S. Sexual desire and arousal disorders in women. Adv Psychosom Med. 2011;31:16–34.PubMedCrossRefGoogle Scholar
  75. 75.
    European Association of Urology (EAU). Non-oncology guidelines [internet]. Male sexual dysfunction, 2017. Accessed 29 May 2017.
  76. 76.
    Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 1996;47(1):129–39.PubMedCrossRefGoogle Scholar
  77. 77.
    Gold SM, Heesen C, Schulz H, Guder U, Monch A, Gbadamosi J, et al. Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg quality of life questionnaire in multiple sclerosis (HAQUAMS). Mult Scler. 2001;7(2):119–30.PubMedCrossRefGoogle Scholar
  78. 78.
    Foley FW, Zemon V, Campagnolo D, Marrie RA, Cutter G, Tyry T, et al. The multiple sclerosis intimacy and sexuality questionnaire—re-validation and development of a 15-item version with a large US sample. Mult Scler. 2013;19(9):1197–203.PubMedCrossRefGoogle Scholar
  79. 79.
    Mohammadi K, Rahnama P, Montazeri A, Foley FW. The multiple sclerosis intimacy and sexuality questionnaire-19: reliability, validity, and factor structure of the Persian version. J Sex Med. 2014;11(9):2225–31.PubMedCrossRefGoogle Scholar
  80. 80.
    Marrie RA, Miller DM, Chelune GJ, Cohen JA. Validity and reliability of the MSQLI in cognitively impaired patients with multiple sclerosis. Mult Scler. 2003;9(6):621–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res. 1995;4(3):187–206.PubMedCrossRefGoogle Scholar
  82. 82.
    Franceschini M, Di Clemente B, Citterio A, Pagliacci MC. Follow-up in persons with traumatic spinal cord injury: questionnaire reliability. Eura Medicophys. 2006;42(3):211–8.PubMedGoogle Scholar
  83. 83.
    Noreau L, Cobb J, Belanger LM, Dvorak MF, Leblond J, Noonan VK. Development and assessment of a community follow-up questionnaire for the Rick Hansen spinal cord injury registry. Arch Phys Med Rehabil. 2013;94(9):1753–65.PubMedCrossRefGoogle Scholar
  84. 84.
    Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron R. Reliability and validity of the incontinence quality of life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil. 2007;88(5):646–52.PubMedCrossRefGoogle Scholar
  85. 85.
    Bonniaud V, Bryant D, Parratte B, Guyatt G. Development and validation of the short form of a urinary quality of life questionnaire: SF-Qualiveen. J Urol. 2008;180(6):2592–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Bonniaud V, Parratte B, Amarenco G, Jackowski D, Didier JP, Guyatt G. Measuring quality of life in multiple sclerosis patients with urinary disorders using the Qualiveen questionnaire. Arch Phys Med Rehabil. 2004;85(8):1317–23.PubMedCrossRefGoogle Scholar
  87. 87.
    Giraldi A, Rellini A, Pfaus JG, Bitzer J, Laan E, Jannini EA, et al. Questionnaires for assessment of female sexual dysfunction: a review and proposal for a standardized screener. J Sex Med. 2011;8(10):2681–706.PubMedCrossRefGoogle Scholar
  88. 88.
    Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30.PubMedCrossRefGoogle Scholar
  89. 89.
    Cappelleri JC, Rosen RC. The sexual health inventory for men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res. 2005;17(4):307–19.PubMedCrossRefGoogle Scholar
  90. 90.
    European Association of Urology (EAU). Non-oncology guidelines [internet]. Neuro-urology, 2017. Accessed 29 May 2017.
  91. 91.
    Rees PM, Fowler CJ, Maas CP. Sexual function in men and women with neurological disorders. Lancet. 2007;369(9560):512–25.PubMedCrossRefGoogle Scholar
  92. 92.
    Lombardi G, Musco S, Wyndaele JJ, Del Popolo G. Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study. Spinal Cord. 2015;53(12):849–54.PubMedCrossRefGoogle Scholar
  93. 93.
    Chen L, Staubli SE, Schneider MP, Kessels AG, Ivic S, Bachmann LM, et al. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. Eur Urol. 2015;68(4):674–80.PubMedCrossRefGoogle Scholar
  94. 94.
    Lombardi G, Nelli F, Celso M, Mencarini M, Del Popolo G. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature. J Sex Med. 2012;9(4):970–85.PubMedCrossRefGoogle Scholar
  95. 95.
    Lombardi G, Musco S, Kessler TM, Li Marzi V, Lanciotti M, Del Popolo G. Management of sexual dysfunction due to central nervous system disorders: a systematic review. BJU Int. 2015;115(Suppl 6):47–56.PubMedCrossRefGoogle Scholar
  96. 96.
    Lombardi G, Macchiarella A, Cecconi F, Del Popolo G. Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. J Sex Med. 2009;6(5):1248–58.PubMedCrossRefGoogle Scholar
  97. 97.
    Shridharani AN, Brant WO. The treatment of erectile dysfunction in patients with neurogenic disease. Transl Androl Urol. 2016;5(1):88–101.PubMedPubMedCentralGoogle Scholar
  98. 98.
    Mittmann N, Craven BC, Gordon M, MacMillan DH, Hassouna M, Raynard W, et al. Erectile dysfunction in spinal cord injury: a cost-utility analysis. J Rehabil Med. 2005;37(6):358–64.PubMedCrossRefGoogle Scholar
  99. 99.
    Moemen MN, Fahmy I, AbdelAal M, Kamel I, Mansour M, Arafa MM. Erectile dysfunction in spinal cord-injured men: different treatment options. Int J Impot Res. 2008;20(2):181–7.PubMedCrossRefGoogle Scholar
  100. 100.
    Montorsi F, Salonia A, Deho F, Cestari A, Guazzoni G, Rigatti P, et al. Pharmacological management of erectile dysfunction. BJU Int. 2003;91(5):446–54.PubMedCrossRefGoogle Scholar
  101. 101.
    Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003;62(1):121–5. discussion 5–6PubMedCrossRefGoogle Scholar
  102. 102.
    Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil—review of the literature. Eur J Med Res. 2002;7(10):435–46.PubMedGoogle Scholar
  103. 103.
    Hong JH, Kwon YS, Kim IY. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. Expert Opin Drug Metab Toxicol. 2017;13(2):183–92.PubMedCrossRefGoogle Scholar
  104. 104.
    Cardenas DD, Ditunno JF, Graziani V, McLain AB, Lammertse DP, Potter PJ, et al. Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury. Spinal Cord. 2014;52(1):70–6.PubMedCrossRefGoogle Scholar
  105. 105.
    Strebel RT, Reitz A, Tenti G, Curt A, Hauri D, Schurch B. Apomorphine sublingual as primary or secondary treatment for erectile dysfunction in patients with spinal cord injury. BJU Int. 2004;93(1):100–4.PubMedCrossRefGoogle Scholar
  106. 106.
    Pohanka M, Kanovsky P, Bares M, Pulkrabek J, Rektor I. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson’s disease induced by pergolide: evidence from the results of an open, prospective, one-year trial. Parkinsonism Relat Disord. 2005;11(8):509–12.PubMedCrossRefGoogle Scholar
  107. 107.
    Rahimi-Movaghar V, Vaccaro AR. Management of sexual disorders in spinal cord injured patients. Acta Med Iran. 2012;50(5):295–9.PubMedGoogle Scholar
  108. 108.
    McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ. 2006;332(7541):589–92.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Hecht SL, Hedges JC. Vacuum therapy for erectile dysfunction. In: Köhler TS, McVary KT, editors. Contemporary treatment of erectile dysfunction: a clinical guide. 2nd ed. Cham: Springer; 2016. p. 175–85.CrossRefGoogle Scholar
  110. 110.
    Chancellor MB, Rivas DA, Panzer DE, Freedman MK, Staas WE Jr. Prospective comparison of topical minoxidil to vacuum constriction device and intracorporeal papaverine injection in treatment of erectile dysfunction due to spinal cord injury. Urology. 1994;43(3):365–9.PubMedCrossRefGoogle Scholar
  111. 111.
    Denil J, Ohl DA, Smythe C. Vacuum erection device in spinal cord injured men: patient and partner satisfaction. Arch Phys Med Rehabil. 1996;77(8):750–3.PubMedCrossRefGoogle Scholar
  112. 112.
    Heller L, Keren O, Aloni R, Davidoff G. An open trial of vacuum penile tumescence: constriction therapy for neurological impotence. Paraplegia. 1992;30(8):550–3.PubMedCrossRefGoogle Scholar
  113. 113.
    Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am. 2001;28(2):335–41. ix-xPubMedCrossRefGoogle Scholar
  114. 114.
    Chen J, Sofer M, Kaver I, Matzkin H, Greenstein A. Concomitant use of sildenafil and a vacuum entrapment device for the treatment of erectile dysfunction. J Urol. 2004;171(1):292–5.PubMedCrossRefGoogle Scholar
  115. 115.
    Canguven O, Bailen J, Fredriksson W, Bock D, Burnett AL. Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction. J Sex Med. 2009;6(9):2561–7.PubMedCrossRefGoogle Scholar
  116. 116.
    John H, Lehmann K, Hauri D. Intraurethral prostaglandin improves quality of vacuum erection therapy. Eur Urol. 1996;29(2):224–6.PubMedGoogle Scholar
  117. 117.
    Cecchi M, Sepich CA, Felipetto R, Vigano L, Pagni G, Minervini R, et al. Vacuum constriction device and topical minoxidil for management of impotence. Arch Esp Urol. 1995;48(10):1058–9.PubMedGoogle Scholar
  118. 118.
    Bellorofonte C, Dell’Acqua S, Mastromarino G, Tombolini P, Ruoppolo M, Zaatar C. External devices: for which patients? Arch Ital Urol Androl. 1995;67(5):293–8.PubMedGoogle Scholar
  119. 119.
    Mulhall JP, Jenkins LC. Vacuum erection device training. In: Mulhall JP, Jenkins LC, editors. Atlas of office based andrology procedures. Cham: Springer; 2017. p. 103–7.CrossRefGoogle Scholar
  120. 120.
    Derouet H, Caspari D, Rohde V, Rommel G, Ziegler M. Treatment of erectile dysfunction with external vacuum devices. Andrologia. 1999;31(Suppl 1):89–94.PubMedGoogle Scholar
  121. 121.
    Althof SE, Turner LA, Levine SB, Bodner D, Kursh ED, Resnick MI. Through the eyes of women: the sexual and psychological responses of women to their partner’s treatment with self-injection or external vacuum therapy. J Urol. 1992;147(4):1024–7.PubMedCrossRefGoogle Scholar
  122. 122.
    Rivas DA, Chancellor MB. Complications associated with the use of vacuum constriction devices for erectile dysfunction in the spinal cord injured population. J Am Paraplegia Soc. 1994;17(3):136–9.PubMedCrossRefGoogle Scholar
  123. 123.
    Narus JB. Intracavernosal injection training. In: Mulhall JP, Jenkins LC, editors. Atlas of office based andrology procedures. Cham: Springer; 2017. p. 117–27.CrossRefGoogle Scholar
  124. 124.
    Bella AJ, Brock GB. Intracavernous pharmacotherapy for erectile dysfunction. Endocrine. 2004;23(2–3):149–55.PubMedCrossRefGoogle Scholar
  125. 125.
    Bodner DR, Lindan R, Leffler E, Kursh ED, Resnick MI. The application of intracavernous injection of vasoactive medications for erection in men with spinal cord injury. J Urol. 1987;138(2):310–1.PubMedCrossRefGoogle Scholar
  126. 126.
    Dinsmore WW, Gingell C, Hackett G, Kell P, Savage D, Oakes R, et al. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study. BJU Int. 1999;83(3):274–9.PubMedCrossRefGoogle Scholar
  127. 127.
    Hirsch IH, Smith RL, Chancellor MB, Bagley DH, Carsello J, Staas WE Jr. Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction. Paraplegia. 1994;32(10):661–4.PubMedCrossRefGoogle Scholar
  128. 128.
    Kapoor VK, Chahal AS, Jyoti SP, Mundkur YJ, Kotwal SV, Mehta VK. Intracavernous papaverine for impotence in spinal cord injured patients. Paraplegia. 1993;31(10):675–7.PubMedCrossRefGoogle Scholar
  129. 129.
    Vidal J, Curcoll L, Roig T, Bagunya J. Intracavernous pharmacotherapy for management of erectile dysfunction in multiple sclerosis patients. Rev Neurol. 1995;23(120):269–71.PubMedGoogle Scholar
  130. 130.
    Deforge D, Blackmer J, Garritty C, Yazdi F, Cronin V, Barrowman N, et al. Male erectile dysfunction following spinal cord injury: a systematic review. Spinal Cord. 2006;44(8):465–73.PubMedCrossRefGoogle Scholar
  131. 131.
    Bednarchik CL, Kottwitz M, Geiger SW. Self-Injection, transurethral, and topical therapy in erectile dysfunction. In: Köhler TS, McVary KT, editors. Contemporary treatment of erectile dysfunction: a clinical guide. 2nd ed. Cham: Springer; 2016. p. 187–207.CrossRefGoogle Scholar
  132. 132.
    Limoge JP, Olins E, Henderson D, Donatucci CF. Minimally invasive therapies in the treatment of erectile dysfunction in anticoagulated cases: a study of satisfaction and safety. J Urol. 1996;155(4):1276–9.PubMedCrossRefGoogle Scholar
  133. 133.
    Nelson CJ, Hsiao W, Balk E, Narus J, Tal R, Bennett NE, et al. Injection anxiety and pain in men using intracavernosal injection therapy after radical pelvic surgery. J Sex Med. 2013;10(10):2559–65.PubMedCrossRefGoogle Scholar
  134. 134.
    Brackett NL, Lynne CM, Ibrahim E, Ohl DA, Sonksen J. Treatment of infertility in men with spinal cord injury. Nat Rev Urol. 2010;7(3):162–72.PubMedCrossRefGoogle Scholar
  135. 135.
    Conejero Sugranes J, Munoz Villellas A, Sarrias Lorenz F, Ramirez GL. Prostaglandin treatment in neurological patients with erectile dysfunction. Arch Esp Urol. 2002;55(1):63–8.PubMedGoogle Scholar
  136. 136.
    Tang SF, Chu NK, Wong MK. Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report. Paraplegia. 1995;33(12):731–3.PubMedCrossRefGoogle Scholar
  137. 137.
    Gordon SA, Stage KH, Tansey KE, Lotan Y. Conservative management of priapism in acute spinal cord injury. Urology. 2005;65(6):1195–7.PubMedCrossRefGoogle Scholar
  138. 138.
    Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated urethral system for erection (MUSE) Study Group. N Engl J Med. 1997;336(1):1–7.PubMedCrossRefGoogle Scholar
  139. 139.
    Mulhall JP, Jenkins LC. Intraurethral alprostadil training. In: Mulhall JP, Jenkins LC, editors. Atlas of office based andrology procedures. Cham: Springer; 2017. p. 113–6.CrossRefGoogle Scholar
  140. 140.
    Lindeborg L, Fode M, Fahrenkrug L, Sonksen J. Satisfaction and complications with the Titan® one-touch release penile implant. Scand J Urol. 2014;48(1):105–9.PubMedCrossRefGoogle Scholar
  141. 141.
    Bettocchi C, Palumbo F, Spilotros M, Lucarelli G, Palazzo S, Battaglia M, et al. Patient and partner satisfaction after AMS inflatable penile prosthesis implant. J Sex Med. 2010;7(1 Pt 1):304–9.PubMedCrossRefGoogle Scholar
  142. 142.
    Natali A, Olianas R, Fisch M. Penile implantation in Europe: successes and complications with 253 implants in Italy and Germany. J Sex Med. 2008;5(6):1503–12.PubMedCrossRefGoogle Scholar
  143. 143.
    Brinkman MJ, Henry GD, Wilson SK, Delk JR, Denny GA, Young M, et al. A survey of patients with inflatable penile prostheses for satisfaction. J Urol. 2005;174(1):253–7.PubMedCrossRefGoogle Scholar
  144. 144.
    Montorsi F, Rigatti P, Carmignani G, Corbu C, Campo B, Ordesi G, et al. AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients. Eur Urol. 2000;37(1):50–5.PubMedCrossRefGoogle Scholar
  145. 145.
    Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol. 2000;164(2):376–80.PubMedCrossRefGoogle Scholar
  146. 146.
    Holloway FB, Farah RN. Intermediate term assessment of the reliability, function and patient satisfaction with the AMS700 Ultrex penile prosthesis. J Urol. 1997;157(5):1687–91.PubMedCrossRefGoogle Scholar
  147. 147.
    Garber BB. Mentor Alpha 1 inflatable penile prosthesis: patient satisfaction and device reliability. Urology. 1994;43(2):214–7.PubMedCrossRefGoogle Scholar
  148. 148.
    Goldstein I, Newman L, Baum N, Brooks M, Chaikin L, Goldberg K, et al. Safety and efficacy outcome of mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol. 1997;157(3):833–9.PubMedCrossRefGoogle Scholar
  149. 149.
    Goldstein I, Bertero EB, Kaufman JM, Witten FR, Hubbard JG, Fitch WP, et al. Early experience with the first pre-connected 3-piece inflatable penile prosthesis: the Mentor Alpha-1. J Urol. 1993;150(6):1814–8.PubMedCrossRefGoogle Scholar
  150. 150.
    Bernal RM, Henry GD. Contemporary patient satisfaction rates for three-piece inflatable penile prostheses. Ther Adv Urol. 2012;2012:707321.Google Scholar
  151. 151.
    Coloplast. Men’s Health. Penile Implants. The Titan® Touch inflatable penile prosthesis and The Genesis® Malleable penile prosthesis, 2017. Accessed 9 Jun 2017.
  152. 152.
    De Lay KJ Jr, Köhler TS. Penile prosthesis. In: Köhler TS, McVary KT, editors. Contemporary treatment of erectile dysfunction: a clinical guide. 2nd ed. Cham: Springer; 2016. p. 209–20.Google Scholar
  153. 153.
    Zermann DH, Kutzenberger J, Sauerwein D, Schubert J, Loeffler U. Penile prosthetic surgery in neurologically impaired patients: long-term followup. J Urol. 2006;175(3 Pt 1):1041–4. discussion 4PubMedCrossRefGoogle Scholar
  154. 154.
    Fode M, Krogh-Jespersen S, Brackett NL, Ohl DA, Lynne CM, Sonksen J. Male sexual dysfunction and infertility associated with neurological disorders. Asian J Androl. 2012;14(1):61–8.PubMedCrossRefGoogle Scholar
  155. 155.
    Collins KP, Hackler RH. Complications of penile prostheses in the spinal cord injury population. J Urol. 1988;140(5):984–5.PubMedCrossRefGoogle Scholar
  156. 156.
    Kabalin JN, Kessler R. Infectious complications of penile prosthesis surgery. J Urol. 1988;139(5):953–5.PubMedCrossRefGoogle Scholar
  157. 157.
    Wilson S, Delk J, Henry GD, Siegel AL. New surgical technique for sphincter urinary control system using upper transverse scrotal incision. J Urol. 2003;169(1):261–4.PubMedCrossRefGoogle Scholar
  158. 158.
    Langston JP, Muneer A, Garaffa G, Ralph D. Complications of penile prosthesis surgery. In: Muneer A, Pearce A, Ralph D, editors. Prosthetic surgery in urology. Cham: Springer; 2016. p. 223–34.CrossRefGoogle Scholar
  159. 159.
    Mulcahy JJ, Carson CC. Long-term infection rates in diabetic patients implanted with antibiotic-impregnated versus nonimpregnated inflatable penile prostheses: 7-year outcomes. Eur Urol. 2011;60(1):167–72.PubMedCrossRefGoogle Scholar
  160. 160.
    Jarow JP. Risk factors for penile prosthetic infection. J Urol. 1996;156(2 Pt 1):402–4.PubMedCrossRefGoogle Scholar
  161. 161.
    Wilson SK, Delk JR. Inflatable penile implant infection: predisposing factors and treatment suggestions. J Urol. 1995;153(3 Pt 1):659–61.PubMedGoogle Scholar
  162. 162.
    Wilson SK, Zumbe J, Henry GD, Salem EA, Delk JR, Cleves MA. Infection reduction using antibiotic-coated inflatable penile prosthesis. Urology. 2007;70(2):337–40.PubMedCrossRefGoogle Scholar
  163. 163.
    Serefoglu EC, Mandava SH, Gokce A, Chouhan JD, Wilson SK, Hellstrom WJ. Long-term revision rate due to infection in hydrophilic-coated inflatable penile prostheses: 11-year follow-up. J Sex Med. 2012;9(8):2182–6.PubMedCrossRefGoogle Scholar
  164. 164.
    Carson CC, Mulcahy JJ, Harsch MR. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of followup. J Urol. 2011;185(2):614–8.PubMedCrossRefGoogle Scholar
  165. 165.
    Nehra A, Carson CC, Chapin AK, Ginkel AM. Long-term infection outcomes of 3-piece antibiotic impregnated penile prostheses used in replacement implant surgery. J Urol. 2012;188(3):899–903.PubMedCrossRefGoogle Scholar
  166. 166.
    Deuk Choi Y, Jin Choi Y, Hwan Kim J, Ki Choi H. Mechanical reliability of the AMS 700CXM inflatable penile prosthesis for the treatment of male erectile dysfunction. J Urol. 2001;165(3):822–4.PubMedCrossRefGoogle Scholar
  167. 167.
    Daitch JA, Angermeier KW, Lakin MM, Ingleright BJ, Montague DK. Long-term mechanical reliability of AMS 700 series inflatable penile prostheses: comparison of CX/CXM and Ultrex cylinders. J Urol. 1997;158(4):1400–2.PubMedCrossRefGoogle Scholar
  168. 168.
    Dubocq F, Tefilli MV, Gheiler EL, Li H, Dhabuwala CB. Long-term mechanical reliability of multicomponent inflatable penile prosthesis: comparison of device survival. Urology. 1998;52(2):277–81.PubMedCrossRefGoogle Scholar
  169. 169.
    Wilson SK, Delk JR, Salem EA, Cleves MA. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med. 2007;4(4 Pt 1):1074–9.PubMedCrossRefGoogle Scholar
  170. 170.
    Kim YD, Yang SO, Lee JK, Jung TY, Shim HB. Usefulness of a malleable penile prosthesis in patients with a spinal cord injury. Int J Urol. 2008;15(10):919–23.PubMedCrossRefGoogle Scholar
  171. 171.
    Lombardi G, Mondaini N, Giubilei G, Macchiarella A, Lecconi F, Del Popolo G. Sacral neuromodulation for lower urinary tract dysfunction and impact on erectile function. J Sex Med. 2008;5(9):2135–40.PubMedCrossRefGoogle Scholar
  172. 172.
    Lombardi G, Nelli F, Mencarini M, Del Popolo G. Clinical concomitant benefits on pelvic floor dysfunctions after sacral neuromodulation in patients with incomplete spinal cord injury. Spinal Cord. 2011;49(5):629–36.PubMedCrossRefGoogle Scholar
  173. 173.
    Alexander M, Rosen RC. Spinal cord injuries and orgasm: a review. J Sex Marital Ther. 2008;34(4):308–24.PubMedCrossRefGoogle Scholar
  174. 174.
    McAlonan S. Improving sexual rehabilitation services: the patient’s perspective. Am J Occup Ther. 1996;50(10):826–34.PubMedCrossRefGoogle Scholar
  175. 175.
    Schopp LH, Kirkpatrick HA, Sanford TC, Hagglund KJ, Wongvatunyu S. Impact of comprehensive gynecologic services on health maintenance behaviours among women with spinal cord injury. Disabil Rehabil. 2002;24(17):899–903.PubMedCrossRefGoogle Scholar
  176. 176.
    Lombardi G, Del Popolo G, Macchiarella A, Mencarini M, Celso M. Sexual rehabilitation in women with spinal cord injury: a critical review of the literature. Spinal Cord. 2010;48(12):842–9.PubMedCrossRefGoogle Scholar
  177. 177.
    Harrison J, Glass CA, Owens RG, Soni BM. Factors associated with sexual functioning in women following spinal cord injury. Paraplegia. 1995;33(12):687–92.PubMedCrossRefGoogle Scholar
  178. 178.
    Westgren N, Hultling C, Levi R, Seiger A, Westgren M. Sexuality in women with traumatic spinal cord injury. Acta Obstet Gynecol Scand. 1997;76(10):977–83.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Jacques Corcos
    • 1
  • Mikolaj Przydacz
    • 1
  1. 1.Department of UrologyJewish General Hospital, McGill UniversityMontrealCanada

Personalised recommendations